Clinical Trials

    Showing 1 - 6 of 6 Ovarian & Fallopian Tube Cancers

    A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

    Status: Enrolling

    Investigator: Aparna Kamat

    Study Coordinator: Jaya Kamath

    Phone: 713.441.6616

    Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells th... Read more >

    A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

    Status: Enrolling

    Investigator: Karolina Kilowski

    Study Coordinator: Jaya Kamath

    Phone: 713.441.6616

    This study will focus on R-DXd in participants with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer. R-DXd is an antibody-drug conjugate that specifically binds to CDH6, which is overexpressed in tumor cells. The ... Read more >

    A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy

    Status: Enrolling

    Investigator: Karolina Kilowski

    Study Coordinator: Jaya Kamath

    Phone: 713.441.6616

    This phase III trial compares the effect of olaparib for one year versus two years, with or without bevacizumab, for the treatment of BRCA 1/2 mutated or homologous recombination deficient stage III or IV ovarian cancer. Olaparib is a polyadenosine 5... Read more >

    A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRa-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

    Status: Enrolling

    Investigator: Karolina Kilowski

    Study Coordinator: Jaya Kamath

    Phone: 713.441.6616

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate recept... Read more >

    A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer (RAMP 301)

    Status: Enrolling

    Investigator: Aparna Kamat

    Study Coordinator: Jaya Kamath

    Phone: 713.441.6616

    This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with defactinib versus Investigator's choice of treatments (ICT) in subjects with recurrent LGSOC who have progressed on a prior platinum-based therapy.... Read more >

    Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial

    Status: Enrolling

    Investigator: Pedro Ramirez

    Study Coordinator: Jaya Kamath

    Phone: 713.441.6616

    This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant chemothera... Read more >